Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from ALX Oncology Holdings ( (ALXO) ) is now available.
On August 12, 2025, ALX Oncology Holdings announced the appointment of Dr. Daniel Curran to its Board of Directors, expanding the board from six to seven members. Dr. Curran brings over 25 years of pharmaceutical experience and currently serves as CEO of Timberlyne Therapeutics. The company also reported significant progress in its clinical programs, particularly highlighting the potential of CD47 expression as a predictive biomarker in cancer treatment. The ASPEN-06 trial demonstrated that patients with high CD47 expression showed a greater response to the evorpacept therapy. ALX Oncology’s strategic focus on CD47-driven approaches and the advancement of its ALX2004 program has extended its cash runway into Q1 2027, positioning the company for multiple data milestones.
The most recent analyst rating on (ALXO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on ALX Oncology Holdings stock, see the ALXO Stock Forecast page.
Spark’s Take on ALXO Stock
According to Spark, TipRanks’ AI Analyst, ALXO is a Underperform.
ALX Oncology Holdings faces significant financial hurdles due to ongoing losses and negative cash flow, reflected in its low financial performance score. The technical analysis indicates a bearish trend with the stock trading below major moving averages. The valuation is challenging due to a negative P/E ratio and lack of dividends. Recent corporate events offer some hope with new leadership appointments, though offset by workforce reductions. Overall, the challenges outweigh the positive aspects, resulting in a low overall stock score.
To see Spark’s full report on ALXO stock, click here.
More about ALX Oncology Holdings
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel therapies to treat cancer and extend patients’ lives. The company is advancing a pipeline that includes the lead product candidate, evorpacept, which is being explored for its potential in various cancer types, leveraging the CD47 expression as a predictive biomarker.
Average Trading Volume: 532,968
Technical Sentiment Signal: Sell
Current Market Cap: $32.84M
Learn more about ALXO stock on TipRanks’ Stock Analysis page.